Loading...
XSTO
STABL
Market cap1mUSD
Dec 05, Last price  
0.25SEK
1D
0.39%
1Q
-25.04%
IPO
-96.49%
Name

Stayble Therapeutics AB

Chart & Performance

D1W1MN
XSTO:STABL chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
24.65%
Rev. gr., 5y
%
Revenues
0k
35,500040,110000000
Net income
-12m
L-47.69%
-1,203,800-2,813,900-6,134,300-7,941,398-16,049,815-12,040,817-24,227,475-23,736,993-12,418,000
CFO
-15m
L-37.69%
-1,392,600-2,617,000-5,422,300289,391-23,982,374-9,632,503-24,885,783-23,536,851-14,666,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
IPO date
Mar 09, 2020
Employees
3
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT